Literature DB >> 17230470

Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias.

Vincent Paillé1, Vincent Henry, Laurent Lescaudron, Philippe Brachet, Philippe Damier.   

Abstract

Parkinson's disease (PD) is characterized by the bilateral degeneration of the midbrain dopamine-containing neurons with the most severe lesion in the posterolateral part of the substantia nigra pars compacta (SNpc). In humans, such lesions lead to specific motor abnormalities (i.e., akinesia, rigidity, and tremor) that are greatly improved by levodopa treatment. After a few years, the beneficial effect of the treatment is frequently offset by the development of dyskinesias. To improve treatment strategies, an animal model showing most of the histological and clinical characteristics of the human disease is mandatory. Ten rats received a bilateral injection of small doses of 6-OHDA in the medial forebrain bundle (MFB) and were compared with five sham-lesioned rats. The 6-OHDA-lesioned rats progressively developed abnormal motor behavior (assessed by the stepping test) compared with the sham-lesioned rats. The lesioned rats greatly improved under levodopa treatment, but developed concomitant dyskinesias. All 6-OHDA-lesioned animals had bilateral partial lesions of the SNpc, with the most severe lesion being in its posterolateral part. There was a significant correlation between the severity of the dopaminergic cell loss and the severity of the levodopa-induced dyskinesias. These rats constitute an interesting model of PD, sharing some of the main characteristics of the human disease. (c) 2006 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17230470     DOI: 10.1002/mds.21308

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  17 in total

1.  Dopamine dysregulation in a mouse model of paroxysmal nonkinesigenic dyskinesia.

Authors:  Hsien-yang Lee; Junko Nakayama; Ying Xu; Xueliang Fan; Maha Karouani; Yiguo Shen; Emmanuel N Pothos; Ellen J Hess; Ying-Hui Fu; Robert H Edwards; Louis J Ptácek
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

2.  Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition.

Authors:  Vincent Paillé; Barbara Picconi; Vincenza Bagetta; Veronica Ghiglieri; Carmelo Sgobio; Massimiliano Di Filippo; Maria T Viscomi; Carmela Giampà; Francesca R Fusco; Fabrizio Gardoni; Giorgio Bernardi; Paul Greengard; Monica Di Luca; Paolo Calabresi
Journal:  J Neurosci       Date:  2010-10-20       Impact factor: 6.167

3.  L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease.

Authors:  K L Eskow Jaunarajs; J A George; C Bishop
Journal:  Neuroscience       Date:  2012-06-01       Impact factor: 3.590

4.  The effects of regular swimming exercise and melatonin on the neurons localized in the striatum of hemiparkinsonian rats.

Authors:  Sinem Gergin; Özlem Kirazlı; Hatice Boracı; Sercan Doğukan Yıldız; Hasan Raci Yananlı; Ümit Süleyman Şehirli
Journal:  Anat Sci Int       Date:  2022-10-12       Impact factor: 1.693

5.  Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.

Authors:  Vincenza Bagetta; Carmelo Sgobio; Valentina Pendolino; Giulia Del Papa; Alessandro Tozzi; Veronica Ghiglieri; Carmela Giampà; Elisa Zianni; Fabrizio Gardoni; Paolo Calabresi; Barbara Picconi
Journal:  J Neurosci       Date:  2012-12-05       Impact factor: 6.167

6.  Pramipexole induced place preference after L-dopa therapy and nigral dopaminergic loss: linking behavior to transcriptional modifications.

Authors:  Simon Loiodice; Poppy Winlow; Sarah Dremier; Etienne Hanon; David Dardou; Omar Ouachikh; Aziz Hafidi; Andre Nogueira da Costa; Franck Durif
Journal:  Psychopharmacology (Berl)       Date:  2016-09-10       Impact factor: 4.530

7.  Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.

Authors:  Melanie A Paquette; Alex A Martinez; Teresa Macheda; Charles K Meshul; Steven W Johnson; S Paul Berger; Andrea Giuffrida
Journal:  Eur J Neurosci       Date:  2012-08-03       Impact factor: 3.386

Review 8.  Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.

Authors:  Elisabetta Tronci; Veronica Francardo
Journal:  J Neural Transm (Vienna)       Date:  2017-12-14       Impact factor: 3.575

Review 9.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

10.  Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian rats.

Authors:  Ippolita Cantuti-Castelvetri; Ledia F Hernandez; Christine E Keller-McGandy; Lauren R Kett; Alex Landy; Zane R Hollingsworth; Esen Saka; Jill R Crittenden; Eduardo A Nillni; Anne B Young; David G Standaert; Ann M Graybiel
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.